These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28590960)

  • 1. NewDrugs 2017, part 2.
    Hussar DA
    Nursing; 2017 Jul; 47(7):28-36. PubMed ID: 28590960
    [No Abstract]   [Full Text] [Related]  

  • 2. New Drugs 2018, part 1.
    Hussar DA
    Nursing; 2018 Feb; 48(2):36-44. PubMed ID: 29324623
    [No Abstract]   [Full Text] [Related]  

  • 3. Elbasvir/grazoprevir, Velpatasvir/sofosbuvir, and Eteplirsen.
    Hussar DA; Tidwell WP
    J Am Pharm Assoc (2003); 2017; 57(1):129-132. PubMed ID: 28038699
    [No Abstract]   [Full Text] [Related]  

  • 4. Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.
    Pisaturo M; Starace M; Minichini C; De Pascalis S; Occhiello L; Fraia AD; Messina V; Sangiovanni V; Claar E; Coppola N;
    Int J Antimicrob Agents; 2020 Sep; 56(3):106067. PubMed ID: 32599227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.
    Heo YA; Deeks ED
    Drugs; 2018 Apr; 78(5):577-587. PubMed ID: 29546556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.
    Asselah T; Boyer N; Saadoun D; Martinot-Peignoux M; Marcellin P
    Liver Int; 2016 Jan; 36 Suppl 1():47-57. PubMed ID: 26725897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-Generation Regimens: The Future of Hepatitis C Virus Therapy.
    Vizuete J; Hubbard H; Lawitz E
    Clin Liver Dis; 2015 Nov; 19(4):707-16, vii. PubMed ID: 26466657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
    Evon DM; Sarkar S; Amador J; Lok AS; Sterling RK; Stewart PW; Reeve BB; Serper M; Reau N; Rajender Reddy K; Di Bisceglie AM; Nelson DR; Golin CE; Lim JK; Fried MW
    J Hepatol; 2019 Sep; 71(3):486-497. PubMed ID: 31096006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of chronic hepatitis C virus infection with crushed elbasvir/grazoprevir administered through a nasogastric tube in a patient with hypoxic encephalopathy.
    Chang WC; Chen HW; Hsieh TY; Lin JC
    Kaohsiung J Med Sci; 2022 Jan; 38(1):77-78. PubMed ID: 34558811
    [No Abstract]   [Full Text] [Related]  

  • 10. New drugs 2016, part 2.
    Hussar DA
    Nursing; 2016 Jul; 46(7):26-33. PubMed ID: 27273173
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of Hepatitis C Virus: An Update on Medications and Patient Education.
    Molino S; Cottreau J
    Orthop Nurs; 2019; 38(4):273-277. PubMed ID: 31343633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drugs 2015, part 2.
    Hussar DA
    Nursing; 2015 Jul; 45(7):34-41; quiz 41-2. PubMed ID: 26083291
    [No Abstract]   [Full Text] [Related]  

  • 13. [High chance of healing for opiate dependent patients].
    Warparkowski A
    MMW Fortschr Med; 2016 Mar; 158(4):75. PubMed ID: 27119898
    [No Abstract]   [Full Text] [Related]  

  • 14. Biochemical Basis of Vosevi, a New Treatment for Hepatitis C
    Besandre R; Liu HW
    Biochemistry; 2018 Feb; 57(5):479-480. PubMed ID: 29185714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.
    de Lédinghen V; Laforest C; Hézode C; Pol S; Renault A; Alric L; Larrey D; Métivier S; Tran A; Jézéquel C; Samuel D; Zoulim F; Tual C; Pailhé A; Gibowski S; Bourlière M; Bellissant E; Pawlotsky JM
    Clin Infect Dis; 2018 Mar; 66(7):1013-1018. PubMed ID: 29077864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Drugs 2020, part 1.
    Hussar DA
    Nursing; 2020 Feb; 50(2):31-38. PubMed ID: 31895198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mavyret and Vosevi--two new combinations for chronic HCV infection.
    Med Lett Drugs Ther; 2017 Oct; 59(1531):166-170. PubMed ID: 28977807
    [No Abstract]   [Full Text] [Related]  

  • 18. [Preclinical and clinical properties of elbasvir (ERELSA
    Kinoshita K; Iwasa T; Asante-Appiah E; Nakamura K
    Nihon Yakurigaku Zasshi; 2017; 150(1):41-53. PubMed ID: 28690275
    [No Abstract]   [Full Text] [Related]  

  • 19. The top 10 drug trends right now.
    Johnson MS
    Nurs Manage; 2013 Jul; 44(7):34-40; quiz 40-1. PubMed ID: 23764906
    [No Abstract]   [Full Text] [Related]  

  • 20. A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
    Duerr M; Schrezenmeier EV; Lehner LJ; Bergfeld L; Glander P; Marticorena Garcia SR; Althoff CE; Sack I; Brakemeier S; Eckardt KU; Budde K; Halleck F
    BMC Nephrol; 2019 Feb; 20(1):36. PubMed ID: 30717681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.